NCT01915732View on ClinicalTrials.gov

A Efficacy and Safety of Duac™Compared With Clindamycin Phosphate Gel in the Treatment of Mild to Moderate Acne Vulgaris

PHASE3CompletedINTERVENTIONAL
Enrollment

1,018

Participants

Timeline

Start Date

April 30, 2013

Primary Completion Date

April 30, 2014

Study Completion Date

April 30, 2014

Conditions
Acne Vulgaris
Interventions
DRUG

Duac™Once Daily Gel

1% clindamycin as clindamycin phosphate and 5% benzoyl peroxide

DRUG

1% clindamycin phosphate gel

1% clindamycin as clindamycin phosphate

Trial Locations (24)

100020

GSK Investigational Site, Beijing

100034

GSK Investigational Site, Beijing

100036

GSK Investigational Site, Beijing

100730

GSK Investigational Site, Beijing

130041

GSK Investigational Site, Changchun

200025

GSK Investigational Site, Shanghai

200032

GSK Investigational Site, Shanghai

200040

GSK Investigational Site, Shanghai

200092

GSK Investigational Site, Shanghai

200433

GSK Investigational Site, Shanghai

210029

GSK Investigational Site, Nanjing

210042

GSK Investigational Site, Nanjing

250022

GSK Investigational Site, Jinan

310003

GSK Investigational Site, Hangzhou

310009

GSK Investigational Site, Hangzhou

400038

GSK Investigational Site, Chongqing

410011

GSK Investigational Site, Changsha

410013

GSK Investigational Site, Changsha

430022

GSK Investigational Site, Wuhan

430071

GSK Investigational Site, Wuhan

510010

GSK Investigational Site, Guangzhou

510080

GSK Investigational Site, Guangzhou

510120

GSK Investigational Site, Guangzhou

710032

GSK Investigational Site, Xian

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT01915732 - A Efficacy and Safety of Duac™Compared With Clindamycin Phosphate Gel in the Treatment of Mild to Moderate Acne Vulgaris | Biotech Hunter | Biotech Hunter